The company announced May 9 that Chiesi will pay a total of $792m for three already-marketed drugs, including the newly-approved Kengreal (cangrelor). The other drugs included in the deal are the antihypertensive Cleviprex (clevidipine) and the rights to the injectable direct thrombin inhibitor Argatroban.
"Today's announcement is strong evidence of our commitment to delivering on our strategic goals, and the transaction itself is a...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
